Aribio to Present Two Research Findings on 'AR1001' at World Congress of Neurology

Aribio announced on September 25 that it will present two new research findings on its oral Alzheimer's disease treatment, AR1001, at the World Congress of Neurology (WCN).

The WCN is the largest international academic conference in the field of neuroscience, held every two years. This year, it will take place from October 12 to 15 at COEX in Seoul. More than 5,000 neuroscientists from over 100 countries are expected to attend, covering the latest research, treatment methods, and policies related to neurological disorders.

At this conference, Fred Kim, President of Aribio USA, will present: ▲ the neuroprotective effect of the phosphodiesterase 5 (PDE5) inhibitor AR1001 on brain nerves damaged by trauma, and ▲ a study on the concordance between plasma phosphorylated tau (pTau) 217 results and amyloid positron emission tomography (PET) in the screening cohort of AR1001's Phase 3 clinical trial.

The first presentation will introduce research results showing that plasma pTau-217 and amyloid PET assessments are consistent in the screening cohort for the AR1001 Phase 3 clinical trial. These findings are expected to have a positive impact on the new drug approval process for AR1001 with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others after the top-line results are announced next year.

The second presentation will highlight research demonstrating the excellent neuroprotective effect of the PDE5 inhibitor AR1001 on brain nerves damaged by traumatic brain injury (TBI). The research team found that AR1001 inhibits neurodegeneration, reduces oxidative stress, and alleviates zinc imbalance following TBI, thereby effectively protecting brain nerves. Going forward, Aribio plans to maximize the scope and value of the new drug by expanding the indications for AR1001.

Aribio has continuously presented research results on AR1001 at various international conferences and neuroscience-related academic meetings, including the U.S. Global Life Sciences Conference, BIO USA, the International Conference on Alzheimer's and Parkinson's Diseases (AD&PD), and the Alzheimer's Association International Conference (AAIC). The company stated, "With the Phase 3 clinical trial set to conclude and top-line results to be announced in the first half of next year, the atmosphere is shifting from anticipation to confidence regarding the oral treatment, as we introduce scientific evidence, clinical efficacy, and results from studies on expanded indications."

Kim stated, "This research confirms that AR1001 has significant potential to expand beyond Alzheimer's disease to a broad range of neurodegenerative disorders," adding, "We expect this to serve as a driving force for actively exploring new indications that can address important unmet needs in the field of neurology."

Meanwhile, Aribio is currently pursuing a merger with Kosdaq-listed company Solux, with the merger date set for January 20, 2026.

This content was produced with the assistance of AI translation services.